Using genomics to refine pediatric AML risk stratification

Area of Science:

• Genomics
• Pediatric Oncology
• Molecular Biology

Background:

• Genomic technologies have significantly advanced the understanding of pediatric acute myeloid leukemia (AML) over the past two decades.
• Cytogenetic tests detect structural changes in ~75% of pediatric AML cases, aiding risk assessment.
• Next-generation sequencing reveals cryptic fusions and mutations impacting disease biology and treatment response.

Purpose of the Study:

• To review the evolving genetic landscape of pediatric AML.
• To highlight novel genetic subtypes and their clinical implications.
• To discuss the potential and challenges of targeted therapies in pediatric AML.

Main Methods:

• Review of recent genomic technologies and their application in pediatric AML research.
• Analysis of identified genetic alterations, including specific fusions (NUP98::NSD1, CBFA2T3::GLIS2, KMT2A) and mutations (NPM1, WT1, DNMT3A, TP53).
• Discussion of emerging targeted therapies (FLT3, BCL2, menin inhibitors).

Main Results:

• Specific genetic fusions define unique childhood AML subtypes with distinct clinical outcomes.
• Certain NPM1 isoforms and mutations in WT1, DNMT3A, and TP53 influence patient prognosis.
• Targeted therapies show promise for personalized treatment but face integration challenges due to AML's complexity.

Conclusions:

• The genetic complexity of pediatric AML necessitates further research to identify prognostic biomarkers.
• Personalized therapy requires accurate prediction of treatment response and effective monitoring strategies.
• Collaborative efforts are crucial for validating biomarkers and optimizing novel drug combinations for pediatric AML.